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1. Introduction
Osteoporosis is a disease entity characterized by the progressive loss of bone mineral density
(BMD) and the deterioration of bone microarchitecture, leading to the development of frac‐
tures. Its classification encompasses two large groups, primary and secondary osteoporosis [1].
Primary osteoporosis is the disease’s most common form and results from the progressive loss
of bone mass related to aging and unassociated with other illness, a natural process in adult
life; its etiology is considered multifactorial and polygenic. This form currently represents a
growing worldwide health problem due in part, to the contemporary environmental condi‐
tions of modern civilization. Risk factors that are considered as “modifiable” also play an
important role and include physical activity, dietary habits and eating disorders. Furthermore,
there is another group of associated risk factors that are considered “non-modifiable”,
including gender, age, race, a personal and/or family history of fractures that in turn, indirectly
reflect the degree of genetic susceptibility to this disease [2-4]. Secondary osteoporosis
encompasses a large heterogeneous group of primary conditions favoring osteoporosis
development. Table 1 summarizes some of the disease entities associated to primary and
secondary osteoporosis.
1.1. Genetic aspects of primary osteoporosis
This form of osteoporosis results from the interaction of several environmental and genetic
factors, leading to difficulties in its study. It is not easy to define the magnitude of the effect of
genetic susceptibility since it is a trait determined by multiple genes whose products affect the
bone phenotype; moreover, the environmental factors compromising bone mineral density are
also difficult to analyze. However, in spite of these barriers, research suggests that inherited
factors affect BMD in ranges between 40 – 70% in the spine, 70 – 85% in the hip and 50 – 60%
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in the wrist. Bone density studies in monozygotic (MZ) and dizygotic (DZ) twins suggest that
spinal and femoral neck BMD concordance is higher (6-8:1) in MZ versus DZ twins. Other
studies have estimated that fracture predisposition heritability per se ranges between 25 – 35%
and up to 40% of patients with osteoporotic fractures have a positive family history of fractures,
thus reflecting the great influence of genetic factors in this disease. On the other hand, the
geometry and length of the femoral neck, the bone’s properties on ultrasound, growth speed
and bone remodeling variations are also dependent on genetic factors. The genes associated
with the bone phenotype are distributed throughout the human genome and located in
practically all chromosomes; their products fulfill specific functions and contribute in different
manners to the genetic control of the bone tissue phenotype [5-12]. Some of these genes and
their products are presented in Table 2 [13-23].
It is important to mention that the mechanisms conditioning the hereditary susceptibility
to  osteoporosis  are  determined,  among  other  factors,  by  the  presence  of  mutations  or
genetic polymorphisms (natural genomic variations) in one or several genes involved in
bone phenotype genetic control.  These polymorphisms follow a well-defined inheritance
pattern and their distribution is different among racial groups and populations. There are
several reports in the world literature, of associations between specific genetic variants and
Type of osteoporosis Causes
Primary Multifactorial, polygenic. Senile/Involutional
Secondary Drugs compromising bone quality: anticonvulsants, antidepressants,
anticoagulants, antacids with aluminum, aromatase inhibitors, barbiturates,
cimetidine, corticosteroids, glucocorticoids, birth control pills, cancer drugs,
gonadotropin releasing hormone (GnRH), loop diuretics, methotrexate,
phenobarbital, phenothiazines, among others.
Other entities: nephropathies, malabsorption syndromes, neoplasias,
rheumatoid arthritis, ankylosing spondylitis, multiple sclerosis, any process
leading to decreased mobility or prolonged immobility.
Metabolic diseases: diabetes, hyperthyroidism, hyperparathyroidism.
Hypogonadism: Turner and Klinefelter syndromes.
Behavioral disorders: anorexia nervosa, depression, prolonged physical
inactivity, malnutrition, high caffeine intake, smoking and/or chronic
alcoholism.
Monogenic diseases: osteogenesis imperfecta, glioma syndrome, osteoporosis.
Table 1. Osteoporosis classification.
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osteoporosis development or the risk of fractures;  these risks may vary according to the
fractures’ anatomic location [3, 4, 24-30]
Product Function Genes
Matrix components COL1A1, COL1A2, OPN
Hormones and their receptors ESR1, ESR2, AR, VDR, PTHR1, CASR, PTH, CYP1A1, PRL, LEP,
LEPR, INS, INSR
Participants in osteoblastogenic proccesses ALOX12, ALOX15, BMP4, BMP7, IGF-1 LRP5, LRP6, SOST
Participants in osteoclastogenic proccesses P53, RANK, RANK-L
Citokines and their receptors IL1α, IL1β, IL6, TNF, TNFR2
Other MTHFR, APOE
Table 2. Genes involved in bone metabolism.
2. Mendelian diseases and osteoporosis
The description in the literature of some genetic diseases of monogenic inheritance and whose
phenotype includes the loss or increase in bone mineral density and even fractures, has
suggested and even proved that bone phenotype has an important genetic component. These
diseases include idiopathic osteoporosis, osteogenesis imperfecta in all its variants, osteopet‐
rosis, pycnodysostosis and the osteoporosis syndrome associated to pseudoglioma, among
others. In some cases of severe osteoporosis, mutations in the estrogen and even the androgen
receptor genes have been detected.
2.1. Idiopathic juvenile osteoporosis
This is an unusual variety of osteoporosis whose frequency has not been precisely determined.
This disease may develop in females and males, usually around 7 – 10 years of age; children
present difficulty in gait, pain in the lower extremities, ankles, knees, occasionally in the hip
and fractures tend to develop particularly in long bones. Radiologically, it is characterized by
diffuse osteopenia, metaphyseal fractures – especially of the femur -, and vertebral collapse
that may lead to severe kyphoscoliosis or collapse of the thoracic cage. This disease is consid‐
ered potentially reversible whereby in most cases, there is almost complete recovery of the
bone tissue; growth, however, may be compromised.
In these patients, it  is important to exclude other disease entities or conditions manifest‐
ing secondarily as osteoporosis. A differential diagnosis must be made with other genetic
diseases, particularly the different variants of osteogenesis imperfecta; this is relatively easy
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due to its  clinical  characteristics,  lacking in idiopathic  osteoporosis.  The genetic  basis  of
this disease has of yet, not been established but it is possible that genetic mutations with
preferential  tissue  expression in  bone and with  great  impact  on the  tissue’s  phenotype,
may explain some of these cases [31, 32].
2.2. Osteogenesis imperfecta
Osteogenesis imperfecta, also known as “brittle bone disease”, has an estimated incidence of
approximately 1 in 20 000 births. It has great phenotypic variability, different patterns of
inheritance and a wide clinical spectrum ranging from very mild forms of the disease to severe
cases with an unfavorable prognosis. It is caused by the defective synthesis of one of the two
alpha chains of type I collagen (COL1A1 and COL1A2), leading to anomalies in these protein’s
structure; it is normally constituted by 3 coiled sub-units, two α1 chains and one α2 chain. This
type of collagen is considered the most abundant component of structural protein in bone as
well as in ligaments, tendons, sclerae and skin. Quantitative or qualitative defects in this
protein lead to bone fragility and hence, to an increased risk of fractures.
The genes encoding the α1 and α2 chains are located in the 17q21.31-q22 and 7q22.1 chromo‐
somes, respectively. Aside from brittle bones, these patients may also present long bones with
no curvatures, severe deformities preventing appropriate gait and even standing, conductive
deafness due to malformations of the auditory canal, dentinogenesis imperfecta, joint hyper‐
laxity and intervertebral disc herniation. Patients with severe forms of the disease have a long
history of fractures on mild impact and variable bone deformities. The most severe variants
may even lead to fractures in utero and pre or perinatal death. Tables 3 and 4 shows different
forms of the disease [33-35].
2.3. Osteoporosis – Pseudoglioma Syndrome (OPPG)
This  syndrome  is  an  autosomal  recessive  disease  characterized  by  bone  and  visual
abnormalities including short stature, osteoporosis development during infancy, spontane‐
ous  fractures,  scoliosis,  platyspondyly  and  long  bone  deformities.  A  crucial  associated
finding is  the presence of  pseudoglioma that  may be associated to microcephaly,  blind‐
ness  during  childhood,  cataracts  and  iris  atrophy.  Occasionally,  some  patients  present
interventricular  septal  defects  and  mental  retardation.  This  disease  is  conditioned  by
mutations of the LRP5 gene,  located on chromosome 11q13.4 and that encodes the low-
density  lipoprotein  receptor-related  protein  5  (LRP5).  It  was  initially  believed  that  this
entity  was  another  variant  of  osteogenesis  imperfecta  (OI)  but  the  study of  collagen in
patients  with  OPPG  established  that  this  protein  was  normal  and  the  hypothesis  was
discarded; however, this is still the most relevant differential diagnosis [36-41].
2.4. Neuromuscular disorders
Muscular dystrophies, peripheral neuropathies and muscle atrophies of hereditary origin,
represent broad groups of diseases that aside from their characteristic clinical stigmata, can be
associated with osteoporosis as one of their complications. As the disease progresses in these
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patients, there is increased difficulty and limitation in walking and periods of immobility
become progressively more prolonged leading to the gradual loss of the mechanical stimuli
that bone needs to maintain its strength and hence, favoring the development of osteoporosis.
As all Mendelian diseases, these neuromuscular abnormalities follow different inheritance
patterns and present phenotypic variability [42-44].
2.5. Inborn errors of metabolism
This group of genetic diseases encompasses a great number of inborn defects with repercus‐
sions in several aspects of carbohydrate, amino acid, protein, vitamin, mineral, complex
molecule, neurotransmitter and energy metabolism. The genetic basis of most of these entities
hinges on gene mutations encoding proteins, particularly enzymes, leading to partial or
complete blockade of one or several metabolic processes. In these diseases, symptoms arise
for different reasons, including: a deficit of the products generated by the compromised
enzymatic reaction, accumulation of the precursor immediate to the defect, an increase in
alternative products due to increased activation of alternate metabolic pathways or inhibition
of these alternate pathways due to the accumulated substrate. In most cases, inheritance of
these diseases is autosomal recessive and less frequently, X-linked recessive.
In cases of metabolic errors, osteoporosis tends to develop for different reasons: in some cases,
it is secondary to nutritional deficiencies, progressive neurologic or muscular impairment or
as a consequence of the therapeutic measures taken in the management of the primary disease:
their secondary effects directly compromise bone quality (steroids, antiseizure drugs, etc.). The
number of monogenic diseases whose phenotype may include osteoporosis is large and are
shown in Tables 3-5, according to their Mendelian inheritance pattern [45-56].








Osteogenesis imperfecta, Type I; OI1 COL1A1 Collagen, type I, alpha
1 (COL1A1)
17q21.33 33, 34
Osteogenesis imperfecta, Type II; OI2 COL1A1 Collagen, type I, alpha
1 (COL1A1)
17q21.33 33, 59
COL1A2 Collagen, type I, alpha
2 (COL1A2)
7q21.3
Osteogenesis imperfecta, Type III; OI3 COL1A1 Collagen, type I, alpha
1 (COL1A1)
17q21.33 33, 60
COL1A2 Collagen, type I, alpha
2 (COL1A2)
7q21.3
Marfan syndrome; MFS FBN1 Fibrillin 1 (FBN1) 15q21.1 61, 62
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Ehlers-Danlos syndrome, Type I COL5A2 Collagen, type V,
alpha 2 (COL5A2)
2q32.2 69, 70
COL5A1 Collagen, type V,
alpha 1 (COL5A1)
9q34.3
COL1A1 Collagen, type I, alpha
1 (COL1A1)
17q21.33
Ehlers-Danlos syndrome, Type II COL5A1 Collagen, type V,
alpha 1 (COL5A1)
9q34.3 70, 71































Disease Gene Product Genomic
Location
Reference






















































disease, primary, 1; PPNAD1
PRKAR1A cAMP-dependent


















Genetic Diseases Related with Osteoporosis
http://dx.doi.org/10.5772/55546
35






































Coronary artery disease, autosomal






Avascular necrosis of femoral head,
primary; ANFH























Disease Gene Product Genomic
Location
Reference










Table 3. Autosomal dominant diseases with bone mineral density loss.
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Disease Gene Product Genomic
location
Reference
Homocysteinemia MTHFR (C677T) Methylenetetrahydro
folate reductase
(MTHFR)







Osteogenesis imperfecta, Type IX;
OI9
[Osteogenesis imperfecta type II-B, III




































Gaucher disease, Type I; GDI GBA Glucosylceramidase
(GLCM/GBA)
1q22 49, 50





Pycnodysostosis; PKND CTSK Cathepsin K 1q21.3 143, 144
Lipodystrophy, congenital
generalized, type 4; CGL4
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Aromatase deficiency CYP19A1 Cytochrome P450
19A1 (CYP19A1)
15q21.2 157, 158
Diastrophic dysplasia SLC26A2 Sulfate transporter 2
(S26A2)
5q32 159, 160





Torg-winchester syndrome MMP2 72 kDa type IV
collagenase (MMP2)
16q12.2 163, 164
Geroderma osteodysplasticum; GO GORAB RAB6-interacting
golgin (GORAB)
1q24.2 165, 166




calcifications and cysts; CRMCC
CTC1 CST complex subunit
CTC1
17p13.1 169, 170
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Macrocephaly, alopecia, cutis laxa,
and scoliosis












Multiple joint dislocations, short
stature, craniofacial dysmorphism,
























ERCC6 DNA excision repair
protein ERCC-6
10q11.23 188, 189
Wilson disease; WND ATP7B Copper-transporting
ATPase 2 (ATP7B)
13q14.3 190, 191





Rothmund-thomson syndrome; RTS RECQL4 ATP-dependent DNA
helicase Q4 (RECQL4)
8q24.3 194, 195
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Cutis laxa, autosomal recessive, Type
IA; ARCL1A
FBLN5 Fibulin-5 (FBLN5) 14q32.12 212, 213
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Laron syndrome GHR Growth hormone
receptor (GHR)
5p13-p12 223, 224





Keutel syndrome MGP Matrix Gla protein
(MGP)
12p12.3 227, 228




isozyme (ALPL / PPBT)
1p36.12 229, 230
Fanconi-Sickel syndrome; FBS SLC2A2 Solute carrier family
2, facilitated glucose
transporter member
2 (SLC2A2 / GTR2)
3q26.2 231, 232










Costello syndrome HRAS GTPase HRas (HRAS/
RASH) (HRAS / RASH)
11p15.5 237, 238
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Table 4. Autosomal recessive diseases with bone mineral density loss.










Androgen insensitivity syndrome; AIS AR Androgen receptor
(AR)
Xq12 243, 244
Fragile X mental retardation
syndrome




Fabry disease GLA Galactosidase, alpha
(AGAL)
Xq22.1 51, 52
Occipital horn syndrome; OHS ATP7A Copper-transporting
ATPase 1 (ATP7A)
Xq21.1 247, 248











(glycerol kinase deficiency; GKD)
GK Glycerol kinase (GK) Xp21.2 253, 254





Terminal osseous dysplasia; TOD or
ODPF
FLNA Filamin-A (FLNA) Xq28 257, 258
Table 5. X-linked recessive diseases with bone mineral density loss.
2.6. Genetic diseases of chromosomal origin and osteoporosis
Within the different categories of genetic diseases, we can include numeric or structural
chromosomal abnormalities. Two of the most common chromosomal diseases are Turner’s
syndrome and Klinefelter’s syndrome, both associated to X chromosome aneuploidy; in the
first case, there is complete or partial absence of an X chromosome and less frequently, it can
be caused by structural anomalies in the short arms of the X chromosome. In Klinefelter’s
syndrome, there is an additional X chromosome and occasionally, there may be more than one
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extra X chromosome. In both syndromes, the phenotypic spectrum includes gonadal dysgen‐
esis, in Turner’s syndrome there are fibrous bands instead of ovaries and in Klinefelter’s, the
testicles are hypoplastic, leading in both cases to hypogonadism and a partial or complete
deficit in the sex hormones that would normally be produced by the ovaries and testicles. Due
to their lack, the development of normal secondary sexual characteristics is stunted and the
various metabolic processes dependent on the hormones are also compromised. One of these
metabolic processes occurs in bone [259-262].
Undoubtedly, bone metabolism is complex and the processes of osteoblastogenesis, osteo‐
clastogenesis and remodeling must occur in a balanced manner; it is important to mention that
the entire family of steroid hormone receptors (estrogen, androgen, vitamin D and retinoids),
are expressed in bone, both in osteoblasts and osteoclasts as well as in chondrocytes. Within
this microenvironment, the action of these hormones on their receptors is key to appropriate
skeletal development; as a matter of fact, individuals with genetic mutations encoding any of
these receptors develop, among other manifestations, bad quality bone mass. These hormones
and their receptors play a pivotal role in female and male bone growth and may also favor
epiphyseal closure at the end of the growth period. It is known that one of effects of steroid
hormones on bone metabolism is resorption inhibition since they promote osteoclast apoptosis
and decrease the frequency of remodeling unit activation. Therefore, the integral treatment of
both entities includes hormone replacement that to a certain extent, will improve bone mass
and will prevent or delay the development of osteoporosis [263, 264].
3. Conclusion
Bone metabolism and the large amount of processes that it involves, such as osteoblastogen‐
esis, osteoclastogenesis and bone remodeling, must be kept in constant balance. Each one
of  these aspects  of  the physiology of  bone shows a particular  gene expression patterns,
which  may  even  differ  according  to  conditions  and  tissue  needs.  As  previously  men‐
tioned the number of genes involved is very large and sometimes their expression might
be  modified  by  multiple  environmental  conditions.  It  is  important  to  mention  that  the
expression  of  these  genes  is  ubiquitous  and  is  not  restricted  to  the  bone  tissue,  which
explains  why the  phenotypic  characteristics  of  a  large  number  of  monogenic  and some
polygenic entities include alterations on bone mineral  density and on the microarchitec‐
ture of this tissue; this includes several degrees of osteopenia,osteoporosis or increased bone
mineral density. Even a good number of these genes have been identified through the study
of human disease whose phenotype includes altered bone mineral density. Without a doubt,
the investigation of several processes that regulate bone metabolism will continue generat‐
ing new knowledge that will allow better understanding of bone physiology and physiopa‐
thology  of  multiple  diseases  and  possibly  new  therapeutic  options  in  diseases  which



















BMP4-Bone Morphogenetic Protein 4
BMP7-Bone Morphogenetic Protein 7
IGF-1-Insulin-Like Growth Factor 1 (Somatomedin C)
SOST-Sclerostin
P53-Protein 53
RANK-Receptor Activator Of Nf-Kb2




TNFR2-Tumor Necrosis Factor Receptor
APOE-Apolipoprotein E
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